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Microbe–host interactions are complex processes that are directly and indirectly regulated
by a variety of factors, including microbe presentation of specific molecular signatures on
the microbial surface, as well as host cell presentation of receptors that recognize these
pathogen signatures. Cell surface glycans are one important class of microbial signatures
that are recognized by a variety of host cell lectins. Host cell lectins that recognize micro-
bial glycans include members of the galectin family of lectins that recognize specific glycan
ligands on viruses, bacteria, fungi, and parasites. In this review, we will discuss the ways
that the interactions of microbial glycans with host cell galectins positively and negatively
regulate pathogen attachment, invasion, and survival, as well as regulate host responses
that mitigate microbial pathogenesis.
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INTRODUCTION
Lectins are proteins that recognize glycan ligands. In mammalian
hosts, different types of endogenous lectins can bind to self glycans,
e.g., selectins that tether circulating leukocytes to the endothelium
or siglecs that regulates signaling in leukocytes by binding to cell
surface glycoprotein receptors (1–4). Also in mammalian hosts,
various types of lectins can recognize glycans that are typically
found on pathogens, but not on host cells, such as mannose bind-
ing protein and dectin-1 that bind high mannose and β-glucan
ligands, respectively, on yeast (5–8). Thus, these types of lectins
have been grouped in the category of pattern recognition recep-
tors (PRRs) that bind pathogen-associated molecular patterns
(PAMPs) expressed exclusively on microbes (9, 10).
However, it is becoming increasingly clear that there are several
lectins that cannot be exclusively segregated into either category
of lectins that only recognize self or lectins that only recognize
non-self. These include some C-type lectins, such as DC-SIGN,
DCIR, and the macrophage mannose receptor, that can recognize
both host and microbial glycans (11–13). Similarly, several mem-
bers of the galectin family can recognize both host and microbial
glycans (14–17). Many C-type lectins and galectins are considered
to be components of the innate immune response to pathogens,
because binding of these lectins to microbial glycans can either
directly or indirectly promote host defense, by triggering leuko-
cyte activation, phagocytosis, complement fixation, and cytokine
production (7, 8, 14). However, some of these same lectins can
also enhance microbial infection of different hosts, an effect that
would seem to be counter-intuitive if lectins are considered to act
solely as host defense molecules (7, 17). Thus, the effects of specific
lectins as pro-microbe or pro-host must always be considered in a
context-dependent manner.
This review will examine roles of galectin family members in
both promoting microbial infection and enhancing host resistance
to infection. The galectins are a family of lectins with a common
carbohydrate recognition domain (CRD), and are found in all
multicellular organisms, including fungi, nematodes, insects, and
vertebrates. Importantly, all galectins are either bivalent or can
multimerize into dimers, pentamers, and higher order oligomers;
the multivalency of galectins allows these molecules to bind mul-
tiple glycan ligands on either the same cell or on opposing cells,
or, in some cases, on microbes and host cells (14, 15, 18).
In many organisms, galectins have been described as partic-
ipating in recognition and defense against microbial pathogens.
Several recent reviews have addressed the indirect effects of
galectins on microbial pathogenesis through regulation of innate
and adaptive immunity, e.g., promoting dendritic cell matura-
tion and migration, enhancing cytokine production, or initiating
release of intracellular mediators such as histamine (14, 15, 19–
21). In contrast, we will specifically address mechanisms by which
galectins directly interact with microbial pathogens to effect three
distinct outcomes – enhancement of microbial infection, blockade
of microbial infection, or microbicidal activity (Figure 1).
GALECTINS PROMOTE MICROBIAL INFECTION
The best-described role for galectins in microbial infections is
to promote pathogen attachment to or entry into host cells. As
galectins are typically multivalent, galectins can bind to glycan
ligands on both the microbial pathogen and the host plasma mem-
brane to“bridge”the microbe to the target cell. This effect has been
described for viruses, bacteria, and parasites.
Sato and colleagues demonstrated that galectin-1 can promote
HIV-1 infection of human T cells and macrophages by promoting
viral adsorption to the target cells (22, 23). This effect was specific
for galectin-1, as galectin-3 did not enhance HIV-1 infection of T
cells or macrophages. Moreover, galectin-1 promoted viral attach-
ment, but did not affect fusion, supporting the“bridging”function
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FIGURE 1 | Host-derived galectins can positively and negatively
regulate microbe–host interactions. (A) Galectins can promote microbial
attachment to and infection of host cells by bridging pathogen glycans to
host cell surface glycans. (B) Galectins can inhibit microbial attachment
and infection by binding to host or microbial glycans and blocking
molecular interactions essential for microbial binding and entry, or by
binding to glycans on nascent microbes, such as budding viruses, and
preventing proper structural assembly. (C) Galectins can be directly
microbicidal, an effect regulated by expression of specific glycan ligands
on the pathogen surface.
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of galectin-1 in this context. Glycoprotein receptors for galectin-1
have been proposed to be gp120 on the virus and CD4 on the
host cells. However, galectin-1 can also bind to CD43 and CD45
on T cells (24, 25); these large glycoproteins are very abundant on
the plasma membrane of these cells, and may also contribute to
adsorption of virus to target cells. In addition, it is known that
budding viral particles can incorporate host cell glycoproteins in
the viral envelope, raising the possibility that host cell glycopro-
teins such as CD45 on the viral envelope may also contribute to
galectin-1 binding (26). A similar mechanism of galectin-1 bridg-
ing virus to host target cells has recently been observed by our
labs for the Nipah virus. Galectin-1 binds to specific glycans on
viral envelope glycoproteins and on the target cell plasma mem-
brane to increase adsorption of virus to target cells, resulting in
increased efficiency of infection of target cells (Garner et al., in
preparation).
Our labs also found that HIV infection of target cells was
promoted by another galectin family member, galectin-9 (27).
However, in this case, enhanced infection was not achieved by
direct “bridging” of the virus to target T cells. Rather, galectin-9
regulated the redox environment at the T cell surface by retain-
ing the thioreductase protein disulfide isomerase (PDI) on the
cell surface; as reduced forms of both the viral Env glycoprotein
gp120 and the T cell counterreceptor CD4 promote viral entry,
the enhancing effect was likely due to the reducing environment
created by galectin-9 retention of PDI.
Both galectin-1 and -3 have been implicated in increasing target
cell infection with human T cell leukemia virus type 1 (HTLV-1)
(28). As described for HIV, galectin-1 was found to stabilize attach-
ment of HTLV-1 to human T cells, resulting in increased efficiency
of infection as well as increased fusion of HTLV-1 infected cells.
Galectin-3 was also found to increase T cell infection by HTLV-1,
although the proposed mechanism differs from the direct bridg-
ing of virus to host cell that has been proposed for galectin-1
and HTLV-1. HTLV-1 forms extracellular viral assemblies, and the
attachment of these viral assemblies to host T cells is promoted by
extracellular matrix proteins such as agrin and collagen, as well as
by cell surface proteins including galectin-3. Unlike the HIV enve-
lope glycoprotein, the HTLV-1 env protein is poorly glycosylated,
so that galectin-3 may bind to these viral assemblies via recognition
of glycans on T cell-derived glycoproteins in these supramolecu-
lar aggregates (29). However, in both cases, the galectin-mediated
interaction results in increased infection of human T cells with
HTLV-1.
A similar bridging function has been proposed for galectin-3
in promoting infection of human corneal epithelial cells by her-
pes simplex virus (HSV)-1 (30). Galectin-3 specifically bound to
HSV-1 in a carbohydrate-dependent manner, but did not bind
the highly related HSV-2, indicating that specific glycans on viral
envelope glycoproteins are determinants of galectin-3 recogni-
tion. Reduction of galectin-3 expression on corneal keratinocytes
reduced HSV-1 binding and infection of the cells, indicating
that galectin-3 can directly promote HSV-1 infection of target
cells.
Direct bridging of pathogen to host target cells has also been
described for enhancement of bacterial adhesion to host cells by
galectins. Galectin-3 specifically increased binding of Neisseria
meningitidis to human monocytes and macrophages, but not
to nasopharyngeal epithelial cells (31). Galectin-3 bound N.
meningitidis lipopolysaccharide (LPS) that bears terminal Lac-
NAc sequences, a preferred glycan ligand for galectin-3. Full-
length galectin-3 was required for this effect; as proteolytic
removal of the N-terminal multimerization domain abrogated the
enhanced binding, this implied that galectin-3 must multimer-
ize for enhancement to occur. In addition, galectin-3 null mice
demonstrated reduced levels of bacteremia, compared to wildtype
mice, after challenge with live N. meningitidis, further implicating
galectin-3 in promoting bacterial infection of host cells. Simi-
larly, LPS from Pseudomonas aeruginosa also bound galectin-3;
galectin-3 is produced by human corneal epithelial cells, a target
of P. aeruginosa infection. Antibodies specific for either the outer
core region of P. aeruginosa LPS or for galectin-3 blocked binding
of bacteria to cultured human corneal epithelial cells, implicat-
ing galectin-3 in corneal infection and development of bacterial
keratitis (32).
Numerous studies have also found roles for galectins in bridg-
ing parasite pathogens to host cells. Leishmania major can bind
both galectin-3 and -9 (33, 34). Galectin-9 binding to polygalac-
tose epitopes on L. major lipophosphoglycans promotes binding
of the parasite to macrophages; specific galectin-9 receptors on the
target cells were not identified, although the authors proposed that
other macrophage lectins, such as the macrophage mannose recep-
tor, may be involved. In contrast to galectin-9, galectin-3 binds L.
major but this resulted in proteolytic cleavage of galectin-3 and
did not promote binding of L. major to macrophages. As the N-
terminal domain of galectin-3 regulates multimerization and the
C-terminal domain of galectin-3 contains the CRD (15), cleaved
galectin-3 would be unable to multimerize; thus, galectin-3 could
not tether the parasite to host cells, because the bridging effect
relies on the multivalency of galectins.
Intriguingly, galectin-mediated bridging of L. major to host
cells is also important at another point in the parasite life cycle.
Valenzuela and co-workers found that a galectin homolog in
the midgut of the sand fly Phlebotomus papatasi participates
in binding of L. major at the procyclic phase to gut epithelial
cells during infection of this obligate insect host (35). The L.
major parasite replicates in the sandfly midgut and differentiates
into the metacyclic phase that is highly infectious to mammalian
hosts and is transmitted during insect bites. Differentiation into
the metacyclic phase coincides with alterations in the parasite
lipophosphoglycans that reduce binding to the sandfly galectin
and allow release of the parasite from the insect gut epithelial
cells. Thus, changes in the parasite surface glycoconjugates can
promote or reduce binding to various types of galectins in both
insect and human hosts at different points during the L. major life
cycle.
Galectin-3 has also been implicated in enhancing infection of
human host cells by the parasite Trypanosoma cruzi. Galectin-3
bound to the surface of T. cruzi trypomastigotes and exogenous
galectin-3 enhanced binding of the parasite to human coro-
nary artery smooth muscle cells. In addition, reducing expres-
sion of endogenous galectin-3 by these cells dramatically reduced
T. cruzi adhesion (36). Galectin-3 also promoted binding of T.
cruzi to extracellular matrix proteins such as laminin (37). As
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T. cruzi infection increases expression of ECM components such
as laminin by host cells, the parasite may use the bridging function
of galectin-3 to accumulate in the basement membranes surround-
ing host target cells such as cardiac myoblasts, thus increasing the
likelihood of infection (38).
Most work on the roles of galectins in promoting microbial
infection has focused on galectins-1, -3, and -9, that are highly
expressed by cells of the immune system as well as endothelial
cells and many types of epithelial cells. Other galectins have a more
restricted expression pattern; for example, galectin-7 is expressed
by squamous epithelial cells. Okumura et al. investigated attach-
ment factors that would promote infection of cervical epithelial
cells by Trichomonas vaginalis (39). This group found that galectin-
1, but not galectin-7, bound to T. vaginalis, although both galectins
were expressed by cervical epithelial cells. Addition of exogenous
galectin-1, but not galectin-7, also enhanced parasite binding to
cervical epithelial cells, while reducing expression of endogenous
galectin-1 in these cells via siRNA decreased parasite binding.
Thus, as has been found for several of the pathogens described
above, there is specific binding of one or more distinct galectin
family members to different microbial pathogens, demonstrating
the unique functions of different galectins at discrete points during
infection.
GALECTINS BLOCK MICROBIAL INFECTION
While it is clear that several galectins can bind to microbial gly-
cans to bridge the microbes to host target cells, galectin binding
to microbial glycans does not always result in a pro-microbe
effect; a microbial glycoprotein that may be available for host
attachment may, at another point in the microbial lifecycle, be a
liability when galectin binding prevents microbial dissemination.
An example of this dichotomy is the interaction of galectin-1 with
the NiV–F fusion protein. As described above, binding of galectin-
1 to Nipah virus envelope glycoproteins can enhance infection
of target endothelial cells by bridging the virus to host plasma
membrane glycoproteins (Garner et al., in preparation). However,
post-infection, the fusion-promoting activity of the NiV–F protein
has a pathogenic effect beyond facilitating viral entry. Endothelial
cells infected with Nipah virus and thus expressing NiV–F at the
plasma membrane fuse with one another to form giant syncytia;
in vivo, this process leads to endothelial cell disruption and death
and is a primary cause of the hemorrhagic diathesis seen in Nipah
virus infection (40–42).
Galectin-1 binding to NiV–F expressed at the plasma mem-
brane prevented cell syncytia formation by three distinct mech-
anisms. First, NiV–F initially appears at the plasma membrane
as an immature precursor that must be endocytosed and prote-
olytically cleaved intracellularly; the cleaved, mature form recy-
cles to the plasma membrane and is fusion-competent. How-
ever, galectin-1 binding to the immature NiV–F protein retards
this essential endocytosis step and thus results in decreased pro-
duction of fusion-competent NiV–F. Second, optimal membrane
fusion requires lateral movement of NiV–F on the plasma mem-
brane; however, galectin-1 binding to NiV–F reduces this lateral
movement and thus reduces the extent of syncytia formation.
Third, NiV–F must undergo a conformational change to effect
the membrane mixing required for fusion, and galectin-1 binding
inhibits this conformational change of NiV–F. While the NiV–
F glycoprotein has five N -glycan attachment sites, one partic-
ular glycan, the F3 glycan, on NiV–F contributed significantly
to all three of these inhibitory effects, i.e., the inhibitory effects
of galectin-1 on NiV–F maturation, movement, and conforma-
tional changes were reduced when the F3 site was mutagenized
to remove the N -glycan (40, 42). As the NiV–F3 glycan was
also important for the bridging effect that enhances NiV entry
into endothelial cells (Garner et al., in preparation), this demon-
strates that the same galectin–glycan interaction that can promote
viral entry at an early time point during infection can reduce
the pathophysiological effect of viral infection at a later time
point.
Finally, the presence of galectin-1 during viral budding reduced
the production of Nipah virus particles from infected endothelial
cells (42). While it is not yet clear whether this effect resulted
specifically and directly from binding of galectin-1 to viral enve-
lope glycoproteins NiV–F or NiV–G, or whether binding of host
plasma membrane glycoproteins by galectin-1 disrupts efficient
viral budding, this observation reinforces the point that the
same lectin, galectin-1, can have a pro-viral or anti-viral effect,
depending on the timing and context of galectin binding to viral
glycoproteins.
Another example of a galectin directly blocking microbial
infection is described in the study by Shiau and colleagues (43);
this group found that galectin-1 can bind directly to envelope
glycoproteins of influenza virus, an effect that impaired virus
infection of target cells in vitro. In addition to demonstrating
this protective effect of galectin-1 in vitro, the authors described
increased expression of galectin-1 in airway epithelia in vivo in a
murine model of influenza virus infection. Moreover, intranasal
administration of recombinant galectin-1 during influenza virus
infection reduced viral load and accompanying inflammation,
tissue damage, and mortality in the murine model, and galectin-
1 null mice were more susceptible to influenza infection than
wildtype mice.
While not directly blocking viral entry, the Panjwani and
Argüeso labs found that galectin-3 can bind to ocular mucins
to contribute to the barrier function of ocular mucins in pre-
venting infection. Thus, while galectin-3 can bind to HSV-1 to
promote viral entry into epithelial cells, as described above (30),
galectin-3 also contributes to reducing HSV-1 entry by organiz-
ing cell surface mucins to maintain mucosal barrier function in
the eye (30, 44), providing another example of a galectin hav-
ing both infection-promoting and infection-reducing effects for a
particular microbial pathogen.
Numerous studies have implicated galectins in promoting a
protective innate or adaptive immune response to pathogens,
although many of the studies have described effects that do not
directly involve binding of the pathogen to a galectin. However,
Schwarz and colleagues have demonstrated that the glycophos-
phatidylinositol (GPIs) on the surface of Toxoplasma gondii can
bind directly to galectin-3 on the surface of macrophages (45).
The binding of these parasite GPIs to cell surface galectin-3, which
associates with TLR2, is essential for TLR2-mediated production
of tumor necrosis factor (TNF) α by the macrophages. As TNFα
is a critical cytokine that promotes parasite clearance, the direct
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interaction of galectin-3 and T. gondii GPIs is an important initial
step to reduce the extent of infection.
Finally, several studies have proposed that galectins in the gas-
trointestinal tract can participate in the organization of mucins
into a protective layer that impedes access of microbial pathogens
to the host epithelium, implying an indirect role for galectins in
reducing microbial invasion. Galectin-4, a galectin that is highly
expressed in gut epithelial cells and has been shown to organize
epithelial plasma membrane domains by binding to specific glyco-
proteins and glycolipids, can bind directly to epithelial glycolipids
that are receptors for pathogens such as Bordetella pertussis and
Helicobacter pylori. This observation gave rise to the hypothe-
sis that galectin-4 may directly impede the ability of bacterial
pathogens to attach to glycolipid receptors and infect host epithe-
lium (46, 47). Experimentally, such a role has been shown for
the Caenorhabditis elegans galectin LEC8, which has significant
homology to mammalian galectins and, like galectin-4, binds gly-
colipids. Ideo et al. found that LEC8 is expressed in the C. elegans
digestive tract, and that LEC8 directly blocked infection of the
worms with Escherichia coli. Moreover, LEC8-deficient animals
were more susceptible to E. coli infection compared to wildtype
worms (48). Thus, depending on the availability of specific micro-
bial glycoprotein receptors for galectins, the anatomic localization
of galectin expression, and the timing of galectin expression dur-
ing infection, galectins may block pathogen binding to and entry
into target cells, rather than enhance binding as described in the
previous section.
GALECTINS HAVE ANTI-MICROBIAL ACTIVITY
Galectins are evolutionarily ancient molecules found in multicel-
lular fungi, nematodes, and insects as well as vertebrates. Thus,
in addition to interfering with pathogen attachment or entry
into host cells, as described above, galectins can act as “danger
receptors” by either enhancing cytokine production or phagocytic
clearance of pathogens by cells of the innate immune system, or
by having direct microbicidal activity.
Early work described galectins associating with microbial
pathogens in phagocytic vesicles, such as the association of
galectin-3 with Mycobacterium tuberculosis in macrophage vesicles
(49). While a direct anti-microbial mechanism was not determined
in this study, galectin-3 null mice had a reduced capacity to clear
M. tuberculosis late in infection, suggesting that galectin-3 had
anti-microbial activity.
A more specific role for galectins in phagocytic clearance of
pathogens was recently described for galectin-8 in defense against
Salmonella typhimurium. Salmonella bacteria invade epithelial
cells and initially reside in a specialized vacuole. The bacteria
generate pores in these vacuoles, damaging the integrity of the
vesicle membrane, which allows the bacteria to access the cytosol
but also releases “danger signals” that initiate autophagy by the
cells to contain the spread of infection. Galectins-1, -3, -8, and
-9 are all recruited to vesicles damaged by endocytosed bacte-
ria, and have all been proposed to participate as “danger-sensing”
molecules; however, specific actions of galectin-1, -3, and -9 in
controlling bacterial damage have not been elucidated. How-
ever, Randow and colleagues found that cytosolic galectin-8 is
a specific and critical component for activation of autophagy
in cells infected with S. typhimurium (50). This group has pro-
posed that cytosolic galectin-8 is recruited to the sites of damaged
vacuoles by binding to glycan ligands on glycoproteins displayed
on the interior face of the vacuoles, although this remains to
be definitively demonstrated. Cells lacking galectin-8 failed to
recruit other molecular components to the damaged vesicles to
initiate autophagy, demonstrating a role for galectin-8 in initi-
ating this critical anti-microbial defense. Randow and colleagues
also found that intracellular galectin-8 was recruited to damaged
endosomes and lysosomes during infection with Listeria mono-
cytogenes or Shigella flexneri, as well as during sterile vesicular
damage, indicating that galectin-8 is a general component in the
autophagy-initiating machinery.
As mentioned above, other galectins have been found associ-
ated with endocytosed or phagocytosed pathogens. A direct role
for galectin-3 in the phagocytosis of helminths such as Schis-
tosoma mansoni has been proposed (51). Galectin-3 can bind
GalNAc–β1,4-GlcNAc (LacdiNAc) sequences found on the surface
of helminths, and can also bind LacdiNAc ligands that are compo-
nents of S. mansoni soluble egg antigen. Addition of recombinant
galectin-3 enhanced recognition and phagocytosis of LacdiNAc-
coated beads by rat macrophages, and galectin-3 was abundantly
expressed in vivo in granulomata containing Schistosoma eggs in
infected hamsters. Thus, galectin-3 has been proposed to play an
important role in the uptake and immunologic “containment” of
parasites within granulomata.
A role for galectin-3 in phagocytosis of yeast has also been
shown. The yeasts Candida albicans and Candida parapsilosis can
be phagocytosed by macrophages and neutrophils. Bliss and col-
leagues found that galectin-3 secreted by neutrophils was impor-
tant for effective phagocytosis of yeast by neutrophils; adding
blocking antibody to galectin-3 reduced phagocytosis, while addi-
tion of exogenous galectin-3 increased phagocytosis (52). Thus,
in neutrophils, galectin-3 appears to act at an early point in
the yeast recognition and engulfment process to enhance uptake
of fungal pathogens. In contrast, an indirect role for galectin-3
in anti-fungal immunity has also been proposed, as galectin-3
has been found to be important for production of the cytokine
TNF-α by macrophages exposed to C. albicans. Using a murine
macrophage cell line, Fink and colleagues found that galectin-3
was not essential for fungal uptake, but that galectin-3 associ-
ated with Dectin-1, a C-type lectin that specifically recognizes
fungal β1,3-glucan in the fungal wall and directly mediated fun-
gal uptake; loss of galectin-3 expression in these cells did not
reduce fungal uptake, but reduced TNF-α production (53). Simi-
larly, Poulain and colleagues found that, while galectin-3 can bind
specific β1,2-mannosides on C. albicans mannoproteins, C. albi-
cans uptake by human monocyte-derived macrophages required
TLR2 but not galectin-3; however, galectin-3 associated with
TLR2 in macrophages that had phagocytosed yeast, and galectin-3
expression by the macrophages was essential for optimal TNF-α
production after yeast phagocytosis (54).
In addition to promoting phagocytic uptake or autophagic
destruction of bacteria, fungi, and parasites, galectins have been
shown to have direct microbicidal activity. As mentioned above,
galectin-3 can recognize specific fungal mannosides on C. albi-
cans. In examining the binding of galectin-3 to intact, live C.
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albicans, Kohatsu et al. observed that galectin-3 binding was
directly fungicidal (55). The effect was dependent on galectin-3
binding to specific glycan ligands on the yeast, and the fungi-
cidal effect was only seen with Candida species that expressed
specific β1,2-oligomannans. Galectin-3 binding to susceptible
yeast resulted in morphologic changes, including cell shrinkage
and increased intracellular granularity. Cell death was confirmed
by a number of assays, and direct fungicidal, rather than fungista-
tic, activity was confirmed. While the mechanism of fungal death
has not been precisely determined, galectin-3 binding appeared
to directly damage the integrity of the cell membrane, given the
observed cell shrinkage and uptake of a fluorescent dye that would
be excluded by intact cells.
A direct microbicidal effect was also demonstrated for galectin-
4 and -8 in the killing of E. coli that express the blood group B
glycans on the cell surface (56). Unlike the autophagy-promoting
activity of intracellular galectin-8 described above (50), addition
of either galectin-4 or -8 to susceptible E. coli strains in the absence
of any host cells resulted in rapid killing of the bacteria, as demon-
strated by loss of membrane integrity and failure of the bacteria
to divide. The complement-independent, rapid, and direct dam-
age to the bacterial membrane is reminiscent of the activity of
galectin-3 on susceptible Candida species, described above. As
with Candida, the mechanism of bacterial death triggered by
galectin binding has not been determined; however, it is tempting
to speculate that the cross-linking of numerous glycoprotein or
glycolipids on the pathogen surface by galectin binding results in
physical changes or mechanical stresses to the surface or interior
of the pathogen that compromise cellular integrity. Stowell and
colleagues propose that the ability of galectins-4 and -8 to directly
kill bacteria is part of an innate immune function of galectins,
providing an important line of defense against gastrointestinal
pathogens.
While not a mammalian defense against microbial pathogens,
another form of microbicidal activity by galectins has been
described for the conger eel (57). This organism expresses two
galectin family members, congerin I and II, in the digestive tract. In
eels infected with parasitic Cucullanus nematodes, these galectins
mediate adhesion of nematodes to peritoneal cells that encapsu-
late and sequester the parasites. This effect may be similar to the
effect of mammalian galectin-3 sequestering Schistosoma eggs in
granulomata in mammalian hosts; while not directly microbicidal,
the effect of encapsulation or sequestering of microbial pathogens
prevents pathogen replication and protects the host.
CONCLUSION
Galectins have been described as PRRs that can discriminate
microbial glycans from host glycans, and as danger receptors that
can participate in innate immune defense. These are certainly
functions of the galectins, but it is becoming increasingly clear
that galectins can bind both host and microbial glycans; thus,
assuming that there is a non-overlapping dichotomy of pathogen
vs. host glycans is not valid. Rather, galectins bind a variety of
glycans in a context-dependent manner on both microbes and
on mammalian cells (58). Moreover, the outcome of binding can
be quite variable, both promoting infection and blocking infec-
tion, and both directly killing microbes and initiating immune
responses; as pathogens evolve in this environment of host gly-
cans and host galectins, microbes may adapt by exploiting these
host features to enhance infection or evade an immune response
(59–62). This broad array of functional outcomes does not reflect
a lack of specificity of the galectins, but rather emphasizes that
specific responses are dependent on both the pathogen and the
host cell and are determined by factors such as glycan density, gly-
can clustering, glycan presentation on specific glycoproteins and
glycolipids, and interactions with other cell surface molecules,
all of which are features that define unique cellular landscapes
in which the galectins act. Thus, as more examples of galectin–
microbe interactions are discovered, it may be possible to begin
to define features of the galectins and glycans that would pre-
dict the outcome of a particular binding event. As galectins are
evolutionarily ancient molecules, predating vertebrate innate and
adaptive immunity, it is not surprising that these lectins have
evolved into a large family with a wide range of context-specific
functions.
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